Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 21, 2025 08:00 ET | Source: AskBio Inc. (AskBio)

AskBio Announces Publication in Nature Medicine of 12-month data from Phase 1 Trial of AB-1002 Gene Therapy in Participants with Congestive Heart Failure

Research Triangle Park, N.C., Oct. 21, 2025 (GLOBE NEWSWIRE) -- First-in-human trial of investigational gene therapy AB-1002 designed to evaluate safety and preliminary efficacy in participants...
October 10, 2025 08:00 ET | Source: AskBio Inc. (AskBio)

AskBio Presents Interim Safety Results from Phase 1/Phase 2 LION-CS101 Clinical Trial of AB-1003 in Participants with Limb-Girdle Muscular Dystrophy 2I/R9

Research Triangle Park, N.C., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Data from first cohort of five participants suggest an acceptable safety profile for AB-1003 in participants with limb-girdle...
October 02, 2025 08:00 ET | Source: AskBio Inc. (AskBio)

AskBio Announces 6 Presentations at the European Society of Gene and Cell Therapy 32nd Annual Meeting

Research Triangle Park, N.C., Oct. 02, 2025 (GLOBE NEWSWIRE) --One oral presentation and five poster presentations will highlight exciting progress in AskBio’s pipeline and advancements in the...
September 22, 2025 06:00 ET | Source: AskBio Inc. (AskBio)

First European Participants Randomized in AskBio Phase 2 Gene Therapy Trial of AB-1005 for Parkinson’s Disease

Research Triangle Park, N.C., Sept. 22, 2025 (GLOBE NEWSWIRE) -- AB-1005, a glial cell line-derived neurotrophic factor (GDNF) investigational gene therapy, is being evaluated for the treatment...
September 17, 2025 08:00 ET | Source: AskBio Inc. (AskBio)

AskBio Announces Completion of Enrollment in Phase 1 Clinical Trial of AB-1005 Gene Therapy for Multiple System Atrophy-Parkinsonian Type (MSA-P)

Research Triangle Park, N.C., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Final participant randomized to complete enrollment in Phase 1 clinical trial assessing safety of investigational gene therapy...
May 27, 2025 08:51 ET | Source: AskBio Inc. (AskBio)

AskBio Announces Publication of Complete Results of Phase 1b Trial of AB-1005 Gene Therapy in Participants with Parkinson’s Disease in Movement Disorders

Research Triangle Park, N.C., May 27, 2025 (GLOBE NEWSWIRE) -- AB-1005 was well tolerated with no attributed serious adverse events in participants with mild or moderate Parkinson’s disease (PD)...
May 19, 2025 08:07 ET | Source: AskBio Inc. (AskBio)

AskBio Presents Complete Results of Phase 1 Trial of AB-1002 Gene Therapy in Participants with Congestive Heart Failure at European Society of Cardiology Heart Failure Meeting

Research Triangle Park, N.C., May 19, 2025 (GLOBE NEWSWIRE) --First-in-human trial of AB-1002 designed to evaluate safety and preliminary efficacy in participants with New York Heart Association...
May 08, 2025 08:00 ET | Source: Asklepios BioPharmaceutical, Inc. (AskBio)

AskBio Announces 15 Presentations at American Society of Gene and Cell Therapy 28th Annual Meeting

Research Triangle Park, N.C., May 08, 2025 (GLOBE NEWSWIRE) --Three oral and 12 poster presentations demonstrate breadth and progress of AskBio’s gene therapy research and development...
April 08, 2025 09:23 ET | Source: Asklepios BioPharmaceutical, Inc. (AskBio)

AskBio Elects Dr. Laura Sepp-Lorenzino Independent Member of Board of Directors

Research Triangle Park, N.C., April 08, 2025 (GLOBE NEWSWIRE) -- Dr. Sepp-Lorenzino brings to AskBio over 30 years of executive, academic, and Board experienceOther Board positions include Taysha...
March 07, 2025 08:00 ET | Source: Asklepios BioPharmaceutical, Inc. (AskBio)

AskBio Advances Gene Therapy Clinical Trial for Limb-Girdle Muscular Dystrophy Type 2I/R9 with Dosing of First Participant in Second Cohort

Research Triangle Park, N.C., March 07, 2025 (GLOBE NEWSWIRE) -- Data Safety Monitoring Board (DSMB) recommendation to initiate second cohort follows review of Phase 1/Phase 2 LION-CS101 trial...